EDIT
Editas Medicine, Inc.
Key Financials
Operating Income
$-160010000
↑ 36.3%
Revenue
$40.5M
↑ 25.4%
Net Income
$-160060000
↑ 32.5%
EPS (Diluted)
$-1.80
↑ 37.5%
Total Assets
$186.5M
↓ 45.4%
Cash & Equivalents
$146.6M
↑ 11.5%
Shareholders' Equity
$27.3M
↓ 79.7%
Total Liabilities
$159.2M
↓ 23.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/9/2026 | View on SEC |
| 3 | 9/9/2026 | View on SEC |
| S-8 | 9/9/2026 | View on SEC |
| EFFECT | 9/8/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| 4 | 9/4/2026 | View on SEC |
| S-3 | 8/31/2026 | View on SEC |
| 144 | 8/31/2026 | View on SEC |
| 144 | 8/31/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | EDIT |
| Company Name | Editas Medicine, Inc. |
| CIK | 1650664 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-401-9000 |